Reaching the Higher Bar for ADC Success: Spotlighting IKS014 Clinical Performance & Understanding Driving Factors for Where ADCs Will Fit Into Treatment Paradigms
2:00 pm - Wednesday 25th February 2026
- Highlighting clinical performance of IKS014 in Phase I development for the treatment of patients with advanced HER2+ solid tumours
- Showcasing the promising preclinical profile of IKS04 targeting CA242 in gastrointestinal cancer
- Addressing the concept of ADC sequencing in future treatment paradigms
